

c-Myc (Phospho Ser373) Rabbit pAb

Catalog#: AP0067 | Size: 30µL/50µL/100µL

Main Information

| Target | Host Species | Reactivity | Application | MW | Conjugated/Modification |
|--------|--------------|-------------------|--------------------|--|-------------------------|
| с-Мус | Rabbit | Human, Mouse, Rat | IHC, IF, IP, ELISA | 50kD,(also ~60kD in some samples) (Observed) | Phospho |

Detailed Information

| Recommeded Dilution Ratio | IHC 1:100-1:300; IP 2-5 ug/mg lysate; ELISA 1:20000; IF 1:50-200 | | |
|---------------------------|--|--|--|
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. | | |
| Specificity | Phospho-c-Myc (S373) Polyclonal Antibody detects endogenous levels of c-Myc protein only when phosphorylated at S373.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):KRsFF | | |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatog- raphy using epitope-specific immunogen. | | |
| Storage | -15°C to -25°C/1 year(Do not lower than -25°C) | | |
| Concentration | 1 mg/ml | | |
| MW(Observed) | 50kD,(also ~60kD in some samples) | | |
| Modification | Phospho | | |
| Clonality | Polyclonal | | |
| Isotype | lgG | | |



Antigen&Target Information

| Immunogen | The antiserum was produced against synthesized peptide derived from human Myc around the phosphorylation site of Ser373. AA range:340-389 | | |
|--------------|--|--|--|
| Specificity | Phospho-c-Myc (S373) Polyclonal Antibody detects endogenous levels of c-Myc protein only when phosphorylated at S373.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):KRsFF | | |
| Gene Name | MYC | | |
| Protein Name | Myc proto-oncogene protein | | |
| Other Name | MYC ;BHLHE39 ;Myc proto-oncogene protein ;Class E basic helix-loop-helix protein 39 ;bHLHe39 ;Proto-oncogene c-Myc ;Transcription factor p64 | | |

Database Link

| Organism | Gene ID | SwissProt |
|----------|---------|-----------|
| Human | 4609 | P01106 |
| Mouse | 17869 | P01108 |
| Rat | 24577 | P09416 |

Background

The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkit-t's lymphomas, suggesting its importance in the normal function of this gene. [provided by RefSeq, Jul 2008].

Function

Disease:A chromosomal aberration involving MYC may be a cause of a form of B-cell chronic lymphocytic leukemia. Translocation t(8;12)(q24;q22) with BTG1.,Disease:Overexpression of MYC is implicated in the etiology of a variety of hematopoietic tumors.,Function:Participates in the regulation of gene transcription. Binds DNA both in a non-specific manner and also specifically to recognizes the core sequence 5'-CAC[GA]TG-3'. Seems to activate the transcription of growth-related genes.,online information:Myc entry,PTM:Phosphorylated by PRKDC.,similarity:Contains 1 basic helix-loop-helix (bHLH) domain.,subunit:Efficient DNA binding requires dimerization with another bHLH protein. Binds DNA as a heterodimer with MAX. Interacts with TAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A and KDM5B.



Cellular Localization

Nucleus, nucleoplasm . Nucleus, nucleolus .

Tissue Expression

Cervix, Epithelium, Leukemia, Placenta, Promyelocytic l

Research Areas


- MAPK signaling pathway
- ErbB signaling pathway
- Cell cycle
- PI3K-Akt signaling pathway
- Cellular senescence
- Wnt signaling pathway
- TGF-beta signaling pathway
- Hippo signaling pathway
- · Signaling pathways regulating pluripotency of stem cells
- JAK-STAT signaling pathway
- Thyroid hormone signaling pathway
- Salmonella infection
- Hepatitis C
- Hepatitis B
- Human cytomegalovirus infection
- Human T-cell leukemia virus 1 infection
- Kaposi sarcoma-associated herpesvirus infection
- Epstein-Barr virus infection
- Pathways in cancer
- Transcriptional misregulation in cancer
- Proteoglycans in cancer
- MicroRNAs in cancer
- Chemical carcinogenesis receptor activation
- Colorectal cancer
- Endometrial cancer
- Thyroid cancer
- Bladder cancer
- · Chronic myeloid leukemia
- Acute myeloid leukemia
- Small cell lung cancer
- Breast cancer
- Hepatocellular carcinoma
- Gastric cancer
- Central carbon metabolism in cancer



Signaling Pathway

Cellular Processes >> Cell growth and death >> Cell cycle Cellular Processes >> Cell growth and death >> Cellular senescence Cellular Processes >> Cellular community - eukaryotes >> Signaling pathways regulating pluripotency of stem cells Organismal Systems >> Endocrine system >> Thyroid hormone signaling pathway Human Diseases >> Cancer: overview >> Pathways in cancer Human Diseases >> Cancer: overview >> Transcriptional misregulation in cancer Human Diseases >> Cancer: overview >> MicroRNAs in cancer Human Diseases >> Cancer: overview >> Central carbon metabolism in cancer Human Diseases >> Cancer: specific types >> Colorectal cancer Human Diseases >> Cancer: specific types >> Hepatocellular carcinoma Human Diseases >> Cancer: specific types >> Gastric cancer Human Diseases >> Cancer: specific types >> Thyroid cancer Human Diseases >> Cancer: specific types >> Acute myeloid leukemia Human Diseases >> Cancer: specific types >> Chronic myeloid leukemia Human Diseases >> Cancer: specific types >> Bladder cancer Human Diseases >> Cancer: specific types >> Endometrial cancer Human Diseases >> Cancer: specific types >> Breast cancer Human Diseases >> Cancer: specific types >> Small cell lung cancer Environmental Information Processing >> Signal transduction >> MAPK signaling pathway Environmental Information Processing >> Signal transduction >> ErbB signaling pathway Environmental Information Processing >> Signal transduction >> Wnt signaling pathway Environmental Information Processing >> Signal transduction >> TGF-beta signaling pathway Environmental Information Processing >> Signal transduction >> Hippo signaling pathway Environmental Information Processing >> Signal transduction >> JAK-STAT signaling pathway Environmental Information Processing >> Signal transduction >> PI3K-Akt signaling pathway

Validation Data



Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using Myc (Phospho-Ser373) Antibody.

Contact Information

📞 +886-32876194 🛛 🐵 www.acebiolab.com 🛛 🕿 Order: order@acebiolab.com 🖉 Support: service@acebiolab.com

RM. 7, 13F., NO. 268, SEC. 1, GAOTIEZHANQIAN W. RD., ZHONGLI DIST., TAOYUAN CITY 320016 , TAIWAN (R.O.C.)

For Research Use Only. Not for Diagnostic Purposes